Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03521154 · OUTCOME

Disease Control Rate by Blinded Independent Central Review (BICR)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
% of participants
Interval / dispersion
95% Confidence Interval
Time frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

What was measured

Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib143
Placebo73

Reported measurements

Source class 1
Values in % of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib88.8Not reported82.593.5Not reported
Placebo79.5Not reported68.488.0Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.94
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.47
    estimate Comment
    An odds ratio \> 1 favours osimertinib.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.069
    param Type
    Odds Ratio (OR)
    param Value
    2.06
    statistical Method
    Regression, Logistic
Complete source fields
analyses
  1. ci Lower Limit
    0.94
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.47
    estimate Comment
    An odds ratio \> 1 favours osimertinib.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.069
    param Type
    Odds Ratio (OR)
    param Value
    2.06
    statistical Method
    Regression, Logistic
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        82.5
        upper Limit
        93.5
        value
        88.8
      2. group Id
        OG001
        lower Limit
        68.4
        upper Limit
        88.0
        value
        79.5
denoms
  1. counts
    1. group Id
      OG000
      value
      143
    2. group Id
      OG001
      value
      73
    units
    Participants
description
Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR
dispersion Type
95% Confidence Interval
groups
  1. description
    80mg once daily tablet
    id
    OG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
Full analysis set
reporting Status
POSTED
time Frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
title
Disease Control Rate by Blinded Independent Central Review (BICR)
type
SECONDARY
unit Of Measure
% of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice